ISIS REPORTS DATA FROM PHASE I LIPID STUDY

ISIS REPORTS DATA FROM PHASE I LIPID STUDY

Isis Pharmaceuticals has announced data from a Phase I study in which ISIS 301012 produced rapid reductions of its target, apoB-100, with concomitant reductions in low density lipoprotein (LDL or "bad" cholesterol).

Less than one month following dosing, healthy volunteers achieved a median reduction of 60 percent in apoB-100 and a median reduction of 54 percent in LDL. In the study, six healthy volunteers with mildly elevated cholesterol levels were treated with approximately 350 mg/week of ISIS 301012 for one month. No treatment-related serious adverse events were reported.